Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

NCT00842257 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Massachusetts General Hospital

Collaborators